bullish

C3.ai Inc

C3.ai, Inc. - IPDs and the Gross Margin Squeeze

105 Views05 Dec 2025 05:13
Issuer-paid
2QFY26 revenue of $75.1 million was essentially on target and cost controls drove a better-than-expected bottom line with EBIT of ($42 million) [Street = ($52 million)].
What is covered in the Full Insight:
  • C3.ai Financial Performance
  • GenSight Overview
  • GenSight's Clinical Programs
  • Innovative Gene Therapy Approaches
  • Growth and Financial Strategy
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x